Management of interleukin-2-induced severe bronchoconstriction.
Suda
T
T
Hashizume
H
H
Aoshima
Y
Y
Yokomura
K
K
Sato
J
J
Inui
N
N
Nakamura
Y
Y
Fujisawa
T
T
Enomoto
N
N
Chida
K
K
D000280:Administration, Inhalation; D000318:Adrenergic beta-Agonists / Q000008:administration & dosage*; D000368:Aged; D000369:Aged, 80 and over; D000420:Albuterol / Q000008:administration & dosage / Q000031:analogs & derivatives*; D000730:Androstadienes / Q000008:administration & dosage*; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage*; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001982:Bronchial Diseases / Q000139:chemically induced* / Q000188:drug therapy*; D001993:Bronchodilator Agents / Q000008:administration & dosage*; D003251:Constriction, Pathologic / Q000139:chemically induced / Q000188:drug therapy; D003692:Delayed-Action Preparations; D004334:Drug Administration Schedule; D005260:Female; D000068298:Fluticasone; D005541:Forced Expiratory Volume / Q000187:drug effects; D006390:Hemangioendothelioma / Q000188:drug therapy*; D006801:Humans; D007262:Infusions, Intravenous; D015552:Injections, Intralesional; D007376:Interleukin-2 / Q000008:administration & dosage / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D011292:Premedication; D000068299:Salmeterol Xinafoate; D012878:Skin Neoplasms / Q000188:drug therapy*
D000318:Adrenergic beta-Agonists; D000730:Androstadienes; D000893:Anti-Inflammatory Agents; D000970:Antineoplastic Agents; D001993:Bronchodilator Agents; D003692:Delayed-Action Preparations; D007376:Interleukin-2; D000068299:Salmeterol Xinafoate; D000068298:Fluticasone; D000420:Albuterol